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ARIOSA DIAGNOSTICS, INC. V. SEQUENOM,
INC.
I. INTRODUCTION
Sequenom is a California based company specializing in
developing molecular technologies including NIPTs (Non-Invasive
Prenatal Genetic Testing), and laboratory developed tests for
genetic diseases and cancer.' At issue here is Sequenom's patent
regarding the methodology and usage of cffDNA.
In 1996, Dr. Dennis Lo and Dr. James Wainscoat, researchers
for Sequenom, discovered a new type of DNA in the blood stream
of an expecting mother called cell free fetal DNA, or cffDNA.2
cffDNA is freely circulating fetal DNA located within the plasma
of the maternal blood stream.3 A particular type of fetal DNA,
paternal cffDNA, allows for the early detection of certain features
of the fetus such as its sex, paternity and a variety of genetic and
chromosomal diseases.' In 2001, Drs. Lo and Wainscoat had
acquired a patent relating to its discovery and methods of use (the
540 patent).'
The 540 patent does not relate to the discovery of cffDNA, but
instead illustrates the methods used to amplify cffDNA to
detectable levels.6 It also includes techniques used in diagnosing
genetic diseases in a fetus based on cffDNA inherited from the
father.7 After the cffDNA is extracted from the maternal plasma,
Sequenom uses methods called polymerase chain reaction (PCR)
and gel electrophoresis to amplify the cffDNA to detectable
levels.8
' Sequenom, Sequenom: The Science of Interpreting the Genome (2015),
http://www.sequenom.com.
2 Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1373 (2015).
3 id.
4 Sequenom, Sequenom: The Science of Interpreting the Genome (2015),
http://www.sequenom.com.
5 Ariosa, 788F.3d at 1373.
6 id.
7 id.
8 id.
1
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A. Ariosa Diagnostics & Appellees
Appellees Ariosa Diagnostics Inc., Natera, Inc., and Diagnostics
Center Inc. are competitors of Sequenom who also specialize in
the development and marketing of non-invasive tests used for the
purpose of diagnosing fetal characteristics and paternity.9
Sequenom's 540 patent negatively impacts Ariosa's ability to
market and develop current and future non-invasive prenatal
genetic tests. If the patent is allowed to stand, Ariosa would most
likely have to cease to market all current and future tests in
development that use the same methods in the 540 patent or risk
litigation. Ariosa could also come to an agreement with Sequenom
to license Sequenom's patent for Ariosa's use. Both options
would place a financial burden on Ariosa which did not previously
exist and could potentially harm the future of the company's
research and development wing.
B. Substantive & Procedural History
Initially, Sequenom sent letters to each of the appellees alleging
patent infringement."0 In response, each appellee asserted that
there was no patent infringement in declaratory judgments."
Sequenom then filed a preliminary injunction against Ariosa to
enjoin them from selling their Harmony Prenatal Test, a DNA
based blood test that detects the presence of certain chromosomal
anomalies signaling disease in a baby." In July 2012, the district
court denied Sequenom's motion for a preliminary injunction and
held that "there was a substantial question over whether the subject
matter of the asserted claims was directed to eligible subject
matter."'" Sequenom then appealed to the federal court of
appeals. "
9 Id. at 1374.
1o Id.
1 Id.
12 id.
13 Id.
14 id.
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In August 2013, the federal court of appeals vacated and
remanded the case in order for the subject matter eligibility to be
examined under Ass'n for Molecular Pathology v. Myriad
Genetics, Inc., 569 U.S. 133 S.Ct. 2107, 2117 (2013)."'" Both
parties then filed for summary judgment.1 6 Sequenom appealed
the district court ruling in favor of Ariosa which stated that
cffDNA was a naturally occurring phenomenon and Sequenom did
not contribute enough to this naturally occurring phenomenon to
deem it eligible under 35 U.S.C § 101.'7 The court emphasized
that Sequenom used PCR and gel electrophoresis, which were
routine methods, and applied them to the naturally occurring
phenomenon of cffDNA.'8 These very steps, the court reasoned,
made Sequenom's claims patent ineligible.'9
II. LEGAL ANALYSIS
In its analysis of the issue, the court re-iterated a two-part test
established in Mayo Collaborative Sers. v. Prometheus Labs.,
Inc., 132 S. Ct. 1289 (2012), which laid out the framework for
determining what a patent eligible concept would look like.
A. Background on Mayo v. Prometheus
Mayo was also a patent infringement case encompassing a
technique to calculate the optimum dose of drugs administered to
patients with autoimmune disease in order to limit its harmful side
effects °.2  The respondent brought action against its competitors
alleging patent infringement on this basis.2 ' The court devised a
two-pronged test to define whether a particular concept is eligible
for patenting.22
"s Id. at 1375.
16 id.
17 id.
18 id.
19 Id.
20 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).
21 Mayo, 132 S. Ct. at 1290, 1291.
22 id.
2015]
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In the first part of this test, the court asked if the claim is
directed to a patent ineligible concept.3 "Phenomena of nature,
mental processes and abstract, intellectual concepts are not
patentable because they are basic tools of scientific and
technological work."24  The court articulated that a patent
involving these concepts may create a type of monopoly that
would work to stifle innovation, rather than promote it.25
The second prong asks whether the concept contains any
conventional steps that would not deem it sufficiently
"inventive".26 A patent focusing on a natural phenomenon must
contain additional components so that it is not merely replicating a
law of nature.27
B. Background on Diamond v. Diehr
Although, the court in Ariosa relied heavily on the Mayo case,
Mayo was heavily distinguished from Diehr.28 In Diehr, the
respondents filed claim to patent the process of creating cured
products from raw, uncured synthetic rubber.29 A part of this
process involved the use of mathematical equations and a
programed computer.3" The court held the process patent eligible
on the basis that the patent claim did not preempt the use of any
one individual step, but the combination of steps as a whole in
order to achieve the same result.3' The court also held when taken
together, all the steps as one process are patent eligible even
though the individual steps in the process were not new, original,
or patent eligible themselves.32
23 Mayo, 132 S. Ct. at 1293, 1294.
24 Gottschalk v. Benson, 409 U.S. 63, 67 (1972).
25 Mayo.132 S. Ct. at 1296.
26 Id. at 1294.
27 Id.
28 Diamondv. Diehr, 101 S. Ct. 1048 (1981).
29 Id. at 177.
30 id.
31 Id. at 188.
32 Id. at 187.
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C. Application of Mayo Test
The court in the present case reasoned that the patented method
started and ended with a natural phenomenon, therefore, the patent
was directed towards a naturally occurring phenomenon.33 The
court supported this reasoning by looking into the description of
the invention notes which stated the surprising discovery of a high
concentration of fetal DNA located in maternal DNA and plasma.3"
Thus, the claim was directed towards a naturally occurring
phenomenon.35
Since the patented method involved a naturally occurring
phenomenon, the court moved on to the second prong of the test.
In the second prong, the court looked at whether the claim
contained an inventive concept sufficient to "transform" the
naturally occurring phenomenon into a patent eligible
application.36
The court concluded that the claim did not include any aspects
that were sufficiently "inventive" in order to deem it eligible for
patenting.37 These aspects when concerning a claim of a certain
method, the court reasoned, must be "new and useful".38
D. Judge Linn's Independent Concurrence
Judge Linn's concurrence recognized that this decision was
possibly an unintended consequence of the broad two-part test set
out in Mayo.39 He stated that although he did not agree with the
outcome of this particular case, the precedent set in Mayo
nonetheless bound him to his decision. n Judge Linn indicated that
the 540 patent should have been eligible."' Although amplification
33 Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1376 (2015).
34 Id.
35 id.
36 id.
31 Id. at 1377.
38 Parker v. Flook, 437 U.S. 584, 591 (1978) ("The process itself, not merely
the mathematical algorithm, must be new and useful.").
39 Ariosa, 788 F.3d at 1380.
40 id.
41 Id. at 1381.
2015]
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through PCR and gel electrophoresis were routine methods, using
it to detect cffDNA was something which had never been done
before.42 Citing Diamond v. Diehr, Judge Linn reasoned that in
Mayo, doctors had already been measuring metabolites, adjusting
dosage and performing the subsequent steps for years in the exact
same way the patent had claimed.43 However, in the present case,
these "routine" steps had never before been performed because the
maternal plasma in which cffDNA is found was frequently
discarded during blood samples.4" 5
III. FUTURE IMPLICATIONS
The implications of this decision will be far reaching. This
ruling will no doubt have a grave impact for future biomarker
patenting methods. With a possible increase in the denial of
patenting biomarker detection methods, a disincentive for
innovation may arise. The court's main goal here was to refrain
from allowing a party to patent essential laws of nature and natural
occurrences because it would inherently stifle innovation.46
However, by interpreting the scope of the Mayo test broadly, the
court has done the very thing they intended to prevent. Many
biomarker detection methods utilize types of "routine" methods in
some shape or form. If these techniques now come under heavy
scrutiny by the courts, it may act as a disincentive for
biotechnology companies to develop new detection methods in this
field.
As future cases with similar facts are heard, courts will have to
narrow down an already far-reaching two-part test. The broad
language of the Mayo test leaves many questions regarding its
scope and application. As patent infringement claims flood the
courts, judges will have to further refine the over-inclusive
42 Id.
41 Id. at 1380.
" Id. at 1380-1381.
45 See, Diamond v. Diehr, 450 U.S. 175, 177 (U.S. 1981) (where the Supreme
Court held that "a new combination of steps in a process may be patentable even
though all the constituents of the combination were well-known and in common
use before the combination was made").
46 Ariosa, 788 F.3d. at 1371.
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vocabulary. Courts will have to define what makes a concept
sufficiently "inventive" as to be eligible for patenting as well as
what exactly constitutes an "abstract idea" or a "law of nature".
Judge Linn's concurrence offers some hope in that it recognizes
there may be a potential problem with the court's broad language
of the Mayo test. Even though Judge Linn concurred with the
Court, he did make it a point to mention that he was bound by
precedent.47 This could potentially open up the door for the
evolution of a similar train of thought in subsequent cases.
Sequenom has recently filed a petition for rehearing en banc
along with many amici briefs for support, many of which were
written by twenty-three law professors who teach and write about
patent law. 8 Their main contention is the court's decision in
Ariosa undermines the principles and notions the patent law
system is designed to protect.4 9 In support of this, they allege the
court's decision was too general and broad and thus contradicts
their own holding in Bilski v. Kappos, 561 U.S. 591 (2010), which
stated that §101 is a "dynamic provision designed to encompass
new and unforeseen inventions.50 The application of Mayo's two-
step test to already past legal patents would today render them
invalid. 1 The brief also asserts that the decision stifles innovation
by not allowing companies to recoup their investment.,2
Companies spend anywhere from $50-$70 million dollars in the
research and development of genetic tests alone and if they cannot
make up for that through patent protections of their products, it
will threaten their financial stability. 3 This will result in the
company ceasing to develop new innovative products for fear of
not being compensated for their work. 4 Recently, Accelerated
Diagnostics alerted its investors that if they are not able to
sufficiently protect its intellectual property, they would incur
47 Ariosa, 788 F.3d at 1380.
48 Brief of Amicus Curiae of Appellant at 1, Ariosa Diagnostics, Inc. v.
Sequenom, Inc., 788 F.3d 1371, 1373 (2015) (No. 2014-1193).
49 Id. at 1.
'o Id. at 1-2.
"' Id. at 2.
52 Id. at 2-3.
13 Id. at 3-4.
14 Id. at 4.
2015]
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heavy losses due to the significant costs that go into marketing and
developing a product.55
IV. CONCLUSION
It is difficult to accurately predict the impact this decision will
have because it was decided so recently. Time will only tell what
the courts will make of this decision and whether they will adopt
the overbroad test or work to narrow the Mayo test over the years
to come. The courts may have their work cut out for them in
trying to narrow and define certain language in the test. The court
has made it clear that the only way to protect your invention is to
keep it a secret for as long as possible. A small positive is
Sequenom's petition for a rehearing en banc. The petition along
with the amicus brief makes a very compelling argument against
the broad, overarching Mayo test. In the meantime, the court's
decision is quite ironic at best; in its attempt to promote
innovation, a closer step was taken towards the suppression of
creativity.
Sukhpal Kooner*
55 Id.
* J.D. Candidate 2017, DePaul University College of Law.
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